Technology

Ethris revolutionizes mRNA therapeutics with its proprietary SNIM® RNA and SNaP LNP® platforms: an integrated, cutting-edge suite enabling safe, stable, and versatile mRNA formulation, manufacturing, and delivery.

About mRNA Technology


Messenger RNA-based therapies are exciting alternatives to gene therapies and protein-based drugs with the potential to treat a wide array of diseases. Messenger RNA (mRNA) is a single strand of nucleotides, which copies genetic information from DNA and carries them to the cells’ protein-making machinery. Unique arrangements of mRNA nucleotide sequences can encode a variety of different proteins, which the body needs to function.


Historically, the use of mRNA as a therapeutic agent has been limited by its inherent instability and tendency to trigger immune responses when introduced into the body in its unmodified form. Moreover, for mRNA to be effective, it must successfully cross cell membranes and be efficiently released within the target cells.

Unlocking the full therapeutic potential of mRNA therefore requires a combination of stabilized, non-immunogenic mRNA molecules and advanced delivery systems that protect and transport the mRNA precisely to target tissues.
Ethris has pioneered this next generation of mRNA therapeutics with its proprietary technology platforms: Stabilized Non-Immunogenic mRNA (SNIM® RNA) and Stabilized Nanoparticle (SNaP LNP®). Together with complementary technologies for mRNA formulation, stabilization, manufacturing, and multi-route delivery, these platforms enable the safe and effective use of mRNA as a true therapeutic modality.

SNIM® RNA platform


Ethris has developed the proprietary Stabilized Non-Immunogenic mRNA (SNIM® RNA) technology: a novel nucleic acid therapy platform based on stabilized non-immunogenic mRNA, which overcomes the innate instability and immunity of mRNA, due to chemical modifications in their structural elements, without altering tranlsational fidelity.

SNIM® RNAs can be administered repeatedly, leading to sustained production of therapeutically active proteins within the human body. Our technology can replace or augment missing or non-functional proteins that cause a disease, introduce new proteins to modulate the course of the disease or its symptoms and be used to develop vaccines. 

SNaP LNP® platform

 

Ethris has developed and optimized a delivery platform based on its proprietary Stabilitzed Lipidoid Nanoparticle (SNaP LNP®) technology with unique properties that allows efficient transport of mRNAs via inhalation to the respiratory tract as well as via intramuscular injection for vaccination.

Storage stability & Lyophilization

Storage and supply chain distribution of mRNA-based therapeutics is a known challenge. Ethris’ proprietary lipidoid formulation has a unique composition and stabilization mix that allows excellent mRNA stability at temperatures ranging from -20°C to room temperature. Ethris has additionally developed lyophilization and rapid rehydration processes, providing product stability for long-term storage and distribution at room temperature. Our formulation is also amenable to spray drying, enabling the production of dry powder forms. Dry powder formulations offer significant advantages, including enhanced stability, elimination of cold-chain requirements, and efficient, targeted delivery to the lower respiratory tract - making them ideal for inhaled therapies in respiratory diseases.


Application

The effective delivery of nanoparticle-based drugs to the upper and lower respiratory tract displays an additional hurdle in their development profile, especially the generation of aerosols and dry powder formulations for inhalation while fully maintaining the integrity and quality of the lipidoid nanoparticle suspension. Ethris’ proprietary lipidoid formulation in combination with an optimized nebulization technology circumvents these hurdles and ensures delivery of potent, high quality and maximum integrity LNP into the respiratory tract with short application times. 

Ethris mRNA LNP Platform Manufacturing
Ethris mRNA LNP Manufacturing Process HPLC free Upstream Downstream

Manufacturing


The success of mRNA therapeutics is highly dependent on stable supply chains and manufacturing capabilities. Ethris has established a supply chain for its raw materials as well as excipients and developed fully-owned, stable and scalable, HPLC-free upstream and downstream manufacturing processes that enable the production of high-quality product candidates for clinical supply. 
Ethris also works closely with a network of qualified contract development and manufacturing organizations (CDMOs) to ensure the highest quality control for its product candidates. 

Explore our Pipeline

PIPELINE

Scientific Publications

  1. Vishwanath S, Carnell GW, Ferrari M, Asbach B, Billmeier M, George C, Sans MS, Nadesalingam A, Huang CQ, Paloniemi M, Stewart H, Chan A, Wells DA, Neckermann P, Peterhoff D, Einhauser S, Cantoni D, Neto MM, Jordan I, Sandig V, Tonks P, Temperton N, Frost S, Sohr K, Ballesteros MTL, Arbabi F, Geiger J, Dohmen C, Plank C, Kinsley R, Wagner R, Heeney JL., A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses. Nat Biomed Eng. 2025 Feb;9(2):153-166. – Learn more.

  2. Macht A, Huang Y, Reinert LS, Grass V, Lohmer K, Aristizabal Prada ET, Babel E, Semmler A, Zhang W, Wegner A, Lichtenegger-Hartl E, Haas S, Hasenpusch G, Meyer S, Paludan SR, Pichlmair A, Rudolph C, Langenickel T., Mucosal IFNλ1 mRNA-based immunomodulation effectively reduces SARS-CoV-2 induced mortality in mice. EMBO Rep. 2024 Sep;25(9):3777-3788  – Learn more.

  3. Vishwanath S, Carnell GW, Billmeier M, Ohlendorf L, Neckermann P, Asbach B, George C, Sans MS, Chan A, Olivier J, Nadesalingam A, Einhauser S, Temperton N, Cantoni D, Grove J, Jordan I, Sandig V, Tonks P, Geiger J, Dohmen C, Mummert V, Samuel AR, Plank C, Kinsley R, Wagner R, Heeney JL., Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants. NPJ Vaccines. 2024 Sep 9;9(1):164. – Learn more.

  4. Hamblet C, Björhall K, Busch S, Gehrmann U, Öberg L, Kubisch-Dohmen R, Haas S, Aneja MK, Geiger J, Rudolph C, Hornberg E., Transcriptional Dynamics of NRF2 Overexpression and KEAP1-NRF2 Inhibitors in Human Cell Line and Primary Lung Cells. Antioxidants (Basel). 2024 Jul 30;13(8):924 – Learn more.

  5. Z. Trepotec, J. Geiger, C. Plank, M.K. Aneja, C. Rudolph, Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life, RNA, 25 (2019) 507-518. – Learn more. 

  6. Z. Trepotec, E. Lichtenegger, C. Plank, M.K. Aneja, C. Rudolph, Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases, Mol Ther, 27 (2019) 794-802. – Learn more.

  7. Z. Trepotec, M.K. Aneja, J. Geiger, G. Hasenpusch, C. Plank, C. Rudolph, Maximizing the Translational Yield of mRNA Therapeutics by Minimizing 5′-UTRs, Tissue Eng Part A, 25 (2019) 69-79. – Learn more.

  8. M. Holstein, C. Mesa-Nunez, C. Miskey, E. Almarza, V. Poletti, M. Schmeer, E. Grueso, J.C. Ordonez Flores, D. Kobelt, W. Walther, M.K. Aneja, J. Geiger, H.B. Bonig, Z. Izsvak, M. Schleef, C. Rudolph, F. Mavilio, J.A. Bueren, G. Guenechea, Z. Ivics, Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors, Mol Ther, 26 (2018) 1137-1153. – Learn more.

  9. Z.S. Badieyan, T. Pasewald, O. Mykhaylyk, C. Rudolph, C. Plank, Efficient ex vivo delivery of chemically modified messenger RNA using lipofection and magnetofection, Biochem Biophys Res Commun, 482 (2017) 796-801. – Learn more.

  10. E. Schrom, M. Huber, M. Aneja, C. Dohmen, D. Emrich, J. Geiger, G. Hasenpusch, A. Herrmann-Janson, V. Kretzschmann, O. Mykhailyk, T. Pasewald, P. Oak, A. Hilgendorff, D. Wohlleber, H.G. Hoymann, D. Schaudien, C. Plank, C. Rudolph, R. Kubisch-Dohmen, Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA, Mol Ther Nucleic Acids, 7 (2017) 350-365. – Learn more. 

  11. M. Utzinger, A. Jarzebinska, N. Haag, M. Schweizer, G. Winter, C. Dohmen, C. Rudolph, C. Plank, cmRNA/lipoplex encapsulation in PLGA microspheres enables transfection via calcium phosphate cement (CPC)/PLGA composites, J Control Release, 249 (2017) 143-149. – Learn more.

  12. M. Ferizi, M.K. Aneja, E.R. Balmayor, Z.S. Badieyan, O. Mykhaylyk, C. Rudolph, C. Plank, Human cellular CYBA UTR sequences increase mRNA translation without affecting the half-life of recombinant RNA transcripts, Sci Rep, 6 (2016) 39149. – Learn more. 

  13. A. Jarzebinska, T. Pasewald, J. Lambrecht, O. Mykhaylyk, L. Kummerling, P. Beck, G. Hasenpusch, C. Rudolph, C. Plank, C. Dohmen, A Single Methylene Group in Oligoalkylamine-Based Cationic Polymers and Lipids Promotes Enhanced mRNA Delivery, Angew Chem Int Ed Engl, 55 (2016) 9591-9595. – Learn more. 

  14. M. Ferizi, C. Leonhardt, C. Meggle, M.K. Aneja, C. Rudolph, C. Plank, J.O. Radler, Stability analysis of chemically modified mRNA using micropattern-based single-cell arrays, Lab Chip, 15 (2015) 3561-3571. – Learn more.